home-slide-2
Focused on Patients The Anaptys Team works to transform patient health by delivering innovative immunology therapeutics. The Anaptys team works to transform patient health by delivering innovative immunology therapeutics.
Theresa, working in the Anaptys lab
home-slide-2
Anaptys Overview A clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases. We are a clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases.
Sarah and Ben in an Anaptys conference room
home-slide-2
The Anaptys Difference Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance. Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance.
home-slide-2
Transparency, Accountability, Humility Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives. Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives.
May and Annie, reviewing a recent Immunology publication
home-slide-2
Webcast Anaptys provides overview of ANB032 a BTLA agonist, at virtual R&D event Anaptys provides overview of ANB032 a BTLA agonist, at virtual R&D event Latest Events

Press Releases

August 29, 2024
  • Anaptys News

Anaptys Announces Participation in September Investor Conferences

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences.

August 14, 2024
  • Anaptys News

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on Aug. 13, 2024.

August 5, 2024
  • Anaptys News

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist

About

Science

Pipeline

Investors

Careers